Skip to content

Global Blood Therapeutics, Inc.

CIK 0001629137

← back to feed
Revenue (TTM)
$41.3M
+11.9% YoY Q2 Aug 2022
Net Income (TTM)
−$304.47M
−390.4% YoY Q2 Aug 2022
EPS Diluted (TTM)
—
Q2 Aug 2022
Gross Margin
90.2%
Q2 Aug 2022
Operating Margin
-683.7%
Q2 Aug 2022
Net Margin
-737.3%
Q2 Aug 2022
Free Cash Flow (TTM)
−$274.01M
Q2 Aug 2022
Cash
$261.15M
Q2 Aug 2022
Total Debt
$247.13M
Q2 Aug 2022
Shares Outstanding
67.46M sh
Q2 Aug 2022

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings